OncLive Staff

Higher doses of anthracyclines are associated with increased risk of breast cancer in women who survived childhood cancer, regardless of whether they have mutations that predispose them to cancer.

A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.

OncLive interviewed experts at the State of the Science Summits in June 2019 on research being conducted at their respective institutions.

The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.

The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.

The FDA has approved the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

A new drug application has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer. ​

Frontline maintenance therapy with olaparib significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial.

A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.

The phase III JAVELIN Ovarian 100 study exploring frontline avelumab in ovarian cancer has been ended after an independent panel determined the study would not meet its primary endpoint of progression-free survival.

The FDA has approved romiplostim for the treatment of pediatric patients aged ≥1 year with immune thrombocytopenia for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) reduced the risk of disease progression or death versus obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

The FDA has granted a priority review to a supplemental new drug application for TAS-102 for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Combining the PD-1 inhibitor pembrolizumab with the VEGF inhibitor axitinib significantly improved survival versus sunitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

The HPV vaccine Gardasil 9 is now approved by the FDA for use in males and females aged 9 through 45 years.

The FDA has granted a priority review to a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma.

As researchers continue to explore immune checkpoints as targets for anticancer therapies, the IDO pathway has emerged as the leading contender to yield the next batch of new drugs in the field.